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ABSTRACT
The characterisation of adrenal tumours has become an important clinical 
issue due to the widespread use of radiological imaging and, thus, the increased 
incidence of clinically unapparent lesions. Most primary tumours of the adrenal 
cortex are benign adenomas, whereas adrenocortical carcinomas (ACCs) remain 
adenomas, making the accurate diagnosis of adrenocortical neoplasms imperative. 
The primary modality for the radiological assessment of adrenal tumours is 
unenhanced computed tomography (CT). A tumour with any malignant features 
require further examination. 
Nonmetastatic tumours must be assessed histologically, identifying adverse 
features indicating malignant potential. The proliferation index (PI) has served as 
a supplemental tool in assessing the malignant potential of adrenocortical tumours.
The study cohorts consisted of consecutive adult patients with primary 
adrenocortical tumours operated on at Helsinki University Central Hospital (HUCH) 
between 2002 and 2008 (study 1) and between 1990 and 2003 (studies II–IV). 
Clinical data, tumour samples and appropriate unenhanced CT scans were collected. 
Tissue microarray (TMA) blocks were constructed for immunohistochemical (IHC) 
examinations.
The proportion of eosinophilic lipid-poor cells in adrenocortical tumours 
correlated with the CT attenuation value by HUs. The attenuation value cannot 
distinguish between lipid-poor adenomas and carcinomas. All carcinomas had 
attenuation values >21 HUs.
The Helsinki score is a histological and immunohistochemical score developed to 
predict the metastatic potential of adrenocortical tumours in adults. Furthermore, 
the Helsinki score uses three individual parameters—mitotic frequency, the presence 
[3 x mitotic activity >5/50 hpf + 5 x presence of necrosis + proliferation %] yields 
a reliable and powerful diagnostic and prognostic system. 
Transcription factor c-myc was shown to express in adrenocortical tumours. 
Benign adenomas show a prominent nuclear c-myc expression comparable to that 
of normal adrenocortical cells, whereas carcinomas show an increased cytoplasmic 
expression. Furthermore, strong cytoplasmic and weak nuclear c-myc expressions 
associate with a malignancy and an adverse outcome. 
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Abstract
Positive mutation–specific isocitrate dehydrogenase 1 (IDH1) R132H 
immunohistochemical (IHC) staining correlates with a better prognosis among 
ACC patients. However, IDH1 R132H IHC does not distinguish between local and 
metastasised tumours. Using a targeted next-generation sequencing (NGS) panel 
and exon sequencing, no mutations to IDH1 could be found 
In conclusion, in the preliminary evaluation of an adrenal tumour, the threshold 
for an indeterminate tumour can be increased from 10 to 20 HUs, at least amongst 
patients with no history of malignancy, since no carcinomas had attenuation values 
The Helsinki score accurately predicts the metastatic potential of adrenocortical 
tumours and the prognosis of carcinoma patients, outperforming the diagnostic 
and prognostic power of previous systems.
Since strong cytoplasmic and weak nuclear c-myc expressions associated with 
malignancy and shorter survival, c-myc IHC can serve as a prognostic marker in 
adrenocortical tumours.
Amongst ACCs, IDH1 R132H immunopositivity correlated with a better 
prognosis, although immunopositivity does not seem to associate with mutations 
to the IDH1 gene.
11
1 INTRODUCTION
Adrenal glands form part of the body’s endocrine system, situated above the kidneys, 
and consisting of two functionally distinct parts: the cortex and the medulla. The 
adrenal cortex secretes corticosteroids and androgens, whilst the medulla secretes 
catecholamines.
10%. Because some nodules are hyperplastic, the incidence of true adrenocortical 
neoplasias remains unknown. However, incidence has recently increased, due to 
the widespread use of radiological imaging, increasing the number of incidentally 
discovered adrenal lesions, or ‘incidentalomas’. Furthermore, the ageing population 
in the Western world contributes to this increasing incidence, since incidence 
typically increases with age.
Most adrenal tumours are benign cortical adenomas detected either through 
imaging. Hormonally active adenomas primarily secrete aldosterone, although 
less frequently they secrete cortisol and very rarely sex steroids. Adrenocortical 
No environmental predisposing factors have been associated with ACAs.
Whilst rare, adrenocortical carcinomas (ACCs) feature a stable annual incidence 
of 1 to 2 cases per 1 million population. The age distribution has two peaks. Most 
than in men, at a ratio of 2.5:1. Most adrenocortical neoplasias are sporadic, arising 
from random mutations of genes involved in the cell’s signaling pathways. However, 
a slightly increased risk for ACC has been linked to smoking. Both adenomas and 
syndrome is Li–Fraumeni, which causes 50% to 80% of paediatric ACCs. Although 
carcinomas are primarily detected based on symptoms caused by excess hormones 
Evaluating adrenal tumours includes a patient history, clinical examination, 
biochemical measurements and radiological imaging. Hormonally active tumours 
are normally operated on to cure the hormone-related syndromes they cause. 
Similarly, any tumours with malignant features must undergo surgery. Amongst 
patients with a history of malignancy, the possibility of metastasis to the adrenal 
gland must be considered. Small, inactive tumours with no malignant features do 
not necessitate operative treatment.
12
1 Introduction
For adenomas, surgical resection represents a curative treatment. However, 
ACC is an aggressive disease carrying a poor prognosis. Thus, ACC patients 
require extensive imaging examinations to rule out metastases, adjuvant therapy 
to prevent recurrence and rigorous follow-up to detect the spread of disease as 
neoplasms imperative (Fassnacht et al. 2018).
and the primary cause of a fatal outcome. In nonmetastatic tumours, the malignant 
potential must be assessed histologically. Since many histological parameters 
associate with malignancy, various histological scoring systems combining multiple 
parameters have been proposed to predict malignancy as accurately as possible. 
The most widely used system is the Weiss scoring system, which includes nine 
histopathological criteria representing adverse features of the tumour, whereby the 
presence of any three of these indicates a malignant potential. The proliferation 
index (PI) has served as a supplemental tool in assessing the malignant potential of 
have been proposed to serve diagnostic and prognostic purposes (Lloyd et al. 2017a). 
13
2 REVIEW OF THE LITERATURE
2.1. Normal adrenal gland
Adrenal glands are yellowish triangular structures situated bilaterally above the 
kidneys embedded in the perirenal fat. The adrenal gland consists of two distinct 
2.1.1. Development
The adrenal cortex derives from the mesoderm and secretes corticosteroids and 
androgens. The adrenal medulla originates from the neural crest and secretes 
catecholamines. During the embryonic period, the intermediate mesoderm of 
the urogenital ridge, together with gonadal primordial cells, gives rise to the 
adrenogonadal primordium at four weeks’ gestation. The adrenal primordium 
then separates from the gonadal primordium. Cells with a neuroectodermal origin 
migrate from the neural crest via the sympathetic ganglion to the developing gland. 
A distinct, encapsulated foetal adrenal gland forms by embryonic week 9. The foetal 
adrenal cortex consists of a predominant foetal zone and a smaller surrounding 
after birth, the foetal zone rapidly involutes, the medullary cells aggregate and the 
2.1.2. Anatomy
The adrenal gland is enveloped by a thick, connective-tissue capsule, from which 
blood supply to the adrenal gland enters from three arteries: the superior, middle and 
inferior suprarenal arteries. These arteries branch before entering the capsule and 
give rise to three kinds of vessels: 1. capsular capillaries that supply the capsule; 2. 
cortical sinusoidal capillaries that supply the cortex and carry blood to the medullary 
capillary sinusoids; and 3. medullary arterioles that pass through the cortex along the 
the activity of the medulla. Venous blood is conveyed from the sinusoids to the 
adrenomedullary connecting veins that coalesce to the central adrenomedullary 
vein and drain into the inferior vena cava on the right side and the left renal vein 
on the left side. The capsule and the medulla contain lymphatic vasculature, but 
14
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not the cortex. The medulla receives abundant innervation from the T10 to the L1 
2014; Ross et al. 2011).
2.1.3. Histology and physiology
Cortex. The adrenal cortex is composed of three zones: the outer zona glomerulosa, 
the thick zona fasciculata in the middle and the inner zona reticularis (see Figure 1).
Figure 1. Histology of the adrenal gland and related hormones.
The cells of the zona glomerulosa are relatively small, forming clusters and columns. 
These cells produce mineralocorticoid aldosterone, which regulates salt and volume 
homeostasis. The zona glomerulosa is under the feedback control of the renin–
angiotensin–aldosterone system. If the blood pressure or the blood sodium level 
decreases, the juxtaglomerular cells in the kidney secrete renin into the bloodstream. 
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Renin then catalyses the conversion of circulating angiotensinogen into angiotensin, 
which, in turn, stimulates the zona glomerulosa to secrete aldosterone.
The zona fasciculata consists of large cells in straight columns. The cells contain 
large droplets of lipids, the precursors for the glucocorticoids and sex steroids 
produced by these cells. The primary function of the glucocorticoids is to regulate 
glucose and fatty acid metabolism. They also depress the immune system. The 
zona fasciculata is regulated by the hypothalamus–pituitary–adrenal (HPA) axis 
(see Figure 2). The circadian rhythm and physical and mental stress stimulate the 
hypothalamus to release the corticotropin-releasing hormone (CRH), which then 
stimulates the release of the adrenocorticotropic hormone (ACTH) from the pituitary 
gland. ACTH stimulates the zona fasciculata cells to produce glucocorticoids. Both 
the secretion of CRH by the hypothalamus and the secretion of ACTH by the pituitary 








Figure 2. Infograph of the hypothalamic–pituitary–adrenal (HPA) axis. CRH, corticotrophin-releasing 
hormone; ACTH, adrenocorticotropic hormone.
16
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The cells of the zona reticularis are small and arranged in anastomosing cords. 
Some of the cells contain lipofuscin pigment granules. The zona reticularis primarily 
produces androgens and to a lesser extent glucocorticoids. Like the zona fasciculata, 
the zona reticularis is also regulated by the HPA axis (Ross et al. 2011; White et 
al. 2008).
Medulla. The parenchyma of the adrenal medulla consists of large pale-staining 
cells (Ross et al. 2011; White et al. 2008).
2.2. Tumours of the adrenal gland
Tumours of the adrenal gland are categorised according to their tissue of origin. 
of the adrenal cortex and medulla. 
Table 1. Classification of tumours of the adrenal gland according to the WHO (2017).
Adrenal cortex Medulla
Adrenal cortical carcinoma Phaeochromocytoma
Adrenal cortical adenoma Neuroblastic tumours of the adrenal gland
Sex cord–stromal tumours Neuroblastoma
Adenomatoid tumour Ganglioneuroblastoma, nodular





Adrenal cortical adenomas and carcinomas represent the primary tumours of the 
originate from other cells and can appear in many organs of the body (Lloyd et 
al. 2017a). In addition to the primary tumours, secondary tumours appear in the 
organs. The most common primary neoplasias metastasing to the adrenal glands 
are melanomas and breast and lung carcinomas (Angelousi et al. 2020).
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is associated with a hereditary genetic susceptibility in about 30% of cases. 
Neuroblastic tumours of the medulla arise from more or less primitive cells of a 
neural crest origin and appear during childhood (Lloyd et al. 2017b).  
In epidemiological settings, adrenal tumours are often grouped together, whilst 
Finnish Cancer Registry collects data from healthcare organisations on cancer cases 
in Finland. As shown in Figure 3, from 1957 to 2017, the incidence of adrenal cancer 
incresed in Finland. This increase in incidence results from advances in diagnostic 
methods across time.
Figure 3. Incidence of adrenal cancer in Finland between 1957 and 2017. Data from the Finnish Cancer Registry.
18
2 Review of the literature
2.3. Adrenocortical neoplasia
2.3.1. Epidemiology
10%. Because some nodules are hyperplastic, the incidence of true ACAs remains 
unknown. However, incidence has recently increased given the widespread use 
of radiological imaging, thereby increasing the number of incidentally discovered 
adrenal lesions (incidentalomas), primarily ACAs. In addition, the ageing population 
both sexes equally.
ACCs are rare, with a steady annual incidence of 0.5 to 2 cases per 1 million 
population. Southern Brazil emerges as a dismal geographical exception in incidence 
given the predisposing founder germline TP53 R337H mutation, where 0.3% of 
et al. 1994; Figueiredo et al. 2006). The age distribution of ACCs features two 
more often than men at a ratio of 2.5:1 (Lloyd et al. 2017a).
2.3.2. Aetiology
Most adrenocortical neoplasias are sporadic arising from random mutations of genes 
involved in the cell’s signaling pathways. No environmental predisposing factors 
have been associated with ACAs. However, a slightly increased risk of ACCs has 
been linked to smoking. Both adenomas and carcinomas associate with hereditary 
–Fraumeni, 
which causes 50% to 80% of paediatric ACCs. Other syndromes involved in the 
pathogenesis of ACCs, their mutated genes and prevalence amongst patients with 
ACCs appear in Table 2. 
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Li–Fraumeni syndrome TP53 3–5% in adults50–80% in children
Lynch syndrome MSH2, MSH6, MLH1, PMS2 3% in adults
Multiple endocrine neoplasia type 1 MEN1 1–2% in adults
Familial adenomatous polyposis APC <1%
Carney complex PRKAR1A <1%
Beckwith–Wiedemann syndrome IGF2, H19 at the 11p15 locus <1%
Neurofibromatosis type 1 NF1 <1%
2.3.3. Clinical presentation
Adrenocortical tumours present in three ways. Hormone-producing tumours are 
usually detected owing to hormone excess–related signs and symptoms. Some 
large and/or malignant tumours present with symptoms such as abdominal pain 
An increasing number of adrenocortical tumours are found incidentally through 
unrelated radiological imaging. These incidentalomas are typically hormonally 
inactive, although some produce subclinical quantities of corticosteroids.
Clinical syndromes caused by hormone excesses are categorised according to 
the hormone in question. A cortisol-producing tumour causes Cushing’s syndrome, 
showing signs and symptoms such as central obesity, muscle weakness, diabetes, 
osteoporosis, hypertension and an impaired immune response.
An aldosterone-producing tumour causes primary hyperaldosteronism, also 
called Conn’s syndrome. Excess aldosterone results in hypertension and hypokalemia 
with symptoms such as muscle weakness, headache and polyuria. Aldosterone is 
primarily produced by adenomas and only rarely by carcinomas.
The sex hormones primarily produced by adrenocortical tumours (ACTs) consist 
of androgens or androgen precursors. Estrogen production is very rare. Signs and 
from hirsutism, virilisation and menstrual disorders. Sex hormone production is 
related to carcinomas more often than to adenomas (Lloyd et al. 2017a).
20
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2.3.4. Pre-operative diagnostics
2.3.4.1. Biochemical measurements
If an adrenal tumour is discovered resulting from an examination associated 
with a hormonal disorder, adequate biochemical measurements have presumably 
should be assessed for signs and symptoms of hormonal excess. The presence of 
any of these signs or symptoms calls for the further biochemical assessment of 
the hormone in question (see Table 3). Even in cases of an asymptomatic and 
apparently nonfunctioning tumour, a 1-mg overnight dexamethasone (DX) test 
is recommended to rule out low-level ‘subclinical’ cortisol excess. Furthermore, 
some tumours produce more than just one hormone. The need to exclude 
phaeochromocytoma in asymptomatic cases remains unclear, although if imaging 
features are indeterminate and if the tumour is not clearly of an adrenocortical origin, 
catecholamines should be tested. Moreover, sex hormones should be measured 
if a carcinoma is suspected, since sex hormone production represents a frequent 
for these measurements vary according to the provider.
Table 3. Hormones secreted by adrenal tumours, indications for measurement, suggested 
methods of measurement and diagnostic cutoff values. The dexamethasone (DX) suppression 
test values are taken from the ‘Clinical Practice Guideline for the Management of Adrenal 
Incidentalomas’ by the European Society of Endocrinology (Fassnacht et al. 2016). Other cutoff 
values represent those used by Helsinki University Central Hospital (HUCH).
Hormone Indication Method Cutoff values
Cortisol
All patients 1-mg dexamethasone 
(DX) suppression test
>138 nmol/l – autonomous 
cortisol secretion
51–138 nmol/l – possible 
autonomous cortisol secretion
If 1-mg DX 
test yields an 
abnormal result 






























According to age and sex
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2.3.4.2. Radiological imaging
The treatment of hormonally active adrenal tumours consists of resection, whilst 
Hormonally inactive tumours, therefore, must be evaluated using radiological 
Unenhanced CT is the primary imaging modality used to assess the nature 
of adrenal tumours. In unenhanced CT, a regular shape, homogenous consistency 
and low density suggest a benign nature. In addition, rounded, peripheral or septal 
require no further medical procedure. In an unenhanced CT, if a tumour presents 
with an attenuation value of >10 HUs or any suspicious radiological characteristics 
such as an irregular shape, heterogenous consistency such as haemorrhagic or 
examinations are needed (Fassnacht et al. 2016).
Contrast-enhanced CT with washout measurements is performed to examine 
any indeterminate tumours. The basis for this imaging modality is that benign 
tumours enhance less and washout the contrast medium more rapidly than 
malignant tumours. A washout CT protocol consists of an unenhanced scan, a 
contrast-enhanced scan with a delay of 60 to 90 s and a delayed scan at 15 min. 
adenoma. Follow-up imaging 6 to 12 months later is recommended for such 
adenomas, if their diameter exceeds 4 cm. If the contrast-enhanced CT is contra-
indicated, a chemical shift magnetic resonance imaging (MRI) can be performed 
whereby signal drop in an out-of-phase versus an in-phase image indicates a benign 
adenoma (Fassnacht et al. 2016).
In addition to the general decision-making guidelines, individual characteristics 
and the patient history should always be taken into account. If the patient has a 
history of malignant disease, metastasis should be considered. If on the basis of 
symptoms, biochemical measurements or imaging characteristics such as a high 
unenhanced CT attenuation value and a delayed washout a phaeochromocytoma 
is suspected, other imaging modalities including PET-CT may be useful (Fassnacht 
et al. 2016; Mayo-Smith et al. 2017 JACR).
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Figure 4. Flowchart of the evaluation of adrenal tumours. Modified from the ‘Clinical Practice Guideline 
for Management of Adrenal Incidentalomas’ by the European Society of Endocrinology (Fassnacht et al. 
2016).
Figure 5. CT scans of adrenocortical tumours. A) Unenhanced CT of an adenoma (circled with green). 
The tumour is small, has a smooth contour and a homogenous consistency. B) Contrast-enhanced CT of a 
carcinoma (circled with red). The tumour is large, has an irregular contour and a heterogenous consistency. 
Enlarged lymph nodes can also be seen (red arrow). Images courtesy of abdominal radiologist Helka 
Parviainen, Helsinki University Central Hospital.
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2.3.5. Surgical treatment
Currently, only hormonally active tumours and tumours with malignant features 
are surgically excised. The entire adrenal gland is typically removed. Apparently, 
benign tumours with a diameter <4 cm can be safely removed by laparoscopy. In 
case of a suspected carcinoma, an open adrenalectomy is recommended and the 
periadrenal fat is then removed with the adrenal gland. Complete resection is a 
priority and the tumour should remain intact during the operation. If the tumour 
invades adjacent structures, these structures should be removed en bloc with the 
adrenal gland. The periadrenal lymph nodes, nodes in the renal hilus and any 
suspicious lymph nodes should also be removed (Gaujoux et al. 2017).
2.3.6. Histopathological diagnosis
Diagnosing an adrenocortical adenoma (ACA) from a surgical adrenalectomy 
specimen is quite straightforward in most cases. Figure 6 shows a macroscopic image 
and microscopic images of an adenoma. Typically, an adenoma is a macroscopically 
yellow or orange sharply delineated tumour, the size of which rarely exceeds 5 
cm. Sometimes an adenoma may contain large amounts of lipofuscin pigment, 
appearing black. Histologically, adenomas consist of fairly large clear cells or smaller 
eosinophilic cells, arranged in cords and nests with small intervening sinusoids. The 
clear cytoplasm results from abundant lipids dissolved during tissue processing. The 
lipids constitute precursors of corticosteroids. Aldosterone-producing adenomas 
typically present with very large clear cells and the surrounding adrenal cortex is 
often micronodular. Cortisol-producing adenomas usually contain smaller cells with 
a more eosinophilic cytoplasm, and the surrounding adrenal cortex is atrophic due 
to excess cortisol (Lloyd et al. 2017a). 
24
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Figure 6. Adrenocortical adenoma: macroscopic and microscopic images. C) An adrenalectomy specimen 
with a sharply circumscribed, homogenous, yellowish adenoma (white arrow). The adrenal gland is indicated 
with a grey arrow. A, B, D and E) Tumour cells are arranged in cords and nests with small intervening 
sinusoids. A, B and D) The cells primarily have a clear cytoplasm and the nuclei are fairly small. E) A 
proportion of the tumour cells are eosinophilic and the nuclei are larger.
glands and, thus, a single unilateral tumour upon radiological imaging favours the 
diagnosis of an adenoma rather than nodular hyperplasia. However, a hyperplastic 
dominant nodule can sometimes grow to become comparatively large and mimic 
an adenoma. In addition, aldosterone-producing adenomas frequently present with 
accompanying micronodular hyperplasia, adding to the confusion. Thus far, no 
and adenoma. In some cases, only post-surgical hormone measurements verify 
the diagnosis (Dekkers et al. 2014; Hellman et al. 2019).
A typical adrenocortical carcinoma (ACC) is a large, brown or reddish tumour 
with areas of haemorrhage and necrosis. A carcinoma might invade adjacent tissues 
and organs. ACC is characterised by malignant histological features including 
atypical mitoses and invasion of vascular structures and the tumour capsule. Figure 7 
provides a macroscopic image and microscopic images of a carcinoma. Nonetheless, 
not all carcinomas present with abundant malignant features and tumours with 
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intermediate characteristics cause diagnostic problems (Lloyd et al. 2017a). To 
tumours, several diagnostic criteria have been proposed and are addressed further 
in the section below on histopathological markers. The mitotic count can be used to 
grade carcinomas into two prognostically relevant groups: low grade <20 mitoses 
et al. 2011; Weiss et al. 1989).
Figure 7. Adrenocortical carcinoma: macroscopic and microscopic images. A) An adrenalectomy specimen, 
where a large tumour is cut in half. The tumour has a heterogenous consistency, variable colour and brown 
haemorrhagic areas. B, C and D) Tumour cells are fairly large, and primarily have an eosinophilic cytoplasm 
and pleomorphic nuclei. C) A necrotic area can be seen, indicated by the white arrow.
Histological variants of ACTs include oncocytic, myxoid and sarcomatoid 
variants, all of which are uncommon. Oncocytic tumours are characterised 
mitochondria. The nuclei of oncocytic tumours are large and have prominent 
can be a mixed tumour (50–90% oncocytes) or completely oncocytic (>90%). Most 
oncocytic tumours present with a favourable prognosis (Lloyd et al. 2017a).
Myxoid
remain debated, since small amounts of degenerative myxoid change can be seen 
in many tumour types. In short, myxoid change is primarily associated with ACC, 
26
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of the tumour patient remains unclear, since large enough series have not been 
studied (de Krijger et al. 2012).
A sarcomatoid ACC is a variant that can present in a monophasic or biphasic 
form. Similar to many other carcinomas, a sarcomatoid component represents a 
In some instances, the origin of an adrenal tumour remains unclear and must be 
This distinction is accomplished through immunohistochemistry (IHC). The 
only protein expressed exclusively in adrenocortical tissue is steroidogenic factor 
between adrenocortical and other neoplasia.
 
Table 4. Immunohistochemistry panel for the differential diagnosis of primary adrenal tumours 















+ +/– + – + –
Phaeochromocytoma 
or paraganglioma – – – + – –
Renal cell carcinoma – + – – – –
Adenocarcinoma – + – – – +/–
Melanoma – – + – – –
Neuroendocrine 
tumour – + – + – +/–
Urothelial carcinoma – + – – – +/–
Hepatocellular 
carcinoma – + – – – –
When diagnosing an ACC, its stage must be determined. The European Network for 
the Study of Adrenal Tumours (ENSAT) staging system, summarised in Table 5, is 
recommended by WHO. In addition to histopathological examination, radiological 
imaging is necessary to determine the stage. The minimum requirement is CT or 
MRI scanning of the thorax, abdomen and pelvis.
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Table 5. The ENSAT staging system according to the TNM status (Fassnacht et al. 2009)
ENSAT stage T N M
I T1 N0 M0
II T2 N0 M0
III T1–T2 N1 M0
T3–T4 N0–N1 M0
IV T1–T4 N0–N1 M1
T1, tumour  5 cm; T2, tumour > 5 cm; T3, infiltration into the surrounding tissue; T4, 
tumour invasion into the adjacent organs or venous tumour thrombus in the vena cava 
or renal vein; N0, no positive lymph nodes; N1, positive lymph node; M0, no distant 
metastases; M1, presence of distant metastases.
2.3.7. Post-operative management of adrenocortical carcinoma (ACC)
When planning treatment for an ACC patient, the tumour stage, resection status, 
proliferation using the Ki-67 index and the patient’s general condition should be 
taken into account. Complete resection of the tumour is required to cure the patient. 
In the case of an incomplete resection, local treatment methods, such as radiation, 
radiofrequency ablation, cryoablation, microwave ablation or chemoembolisation 
can be used. Even when the tumour is completely removed, adjuvant therapy is 
used in most cases to prevent recurrence (Fassnacht et al. 2018).
2.3.7.1. Adjuvant therapy by mitotane
Mitotane is an adrenolytic agent, a derivative of the insecticide DDT, and has been 
used to treat ACC since 1959. The action of mitotane partly relies on the inhibition 
adrenocortical tissue remains unknown. First, mitotane was only used for inoperable 
or disseminated cases of ACC, but was later employed as an adjuvant therapy to 
studies and bias related to patient selection. No randomised prospective clinical 
trials have been published on mitotane as an adjuvant treatment. However, in a 
meta-analysis by the European Society of Endocrinology (ESE), mitotane appears 
The therapeutic response of mitotane is achieved at a plasma level of 14 mg/l, 
whereas a plasma concentration above 20 mg/l results in toxicity. Mitotane plasma 
levels are, thus, monitored rigorously during treatment. Even within the therapeutic 
In the ESE ‘Clinical Practice Guideline’, mitotane treatment is recommended 
for patients with metastatic or residual disease and as an adjuvant treatment for 
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patients with a high risk of recurrence (stage III, proliferation >10%). For patients 
with a completely resected local tumour and a low risk of recurrence (stages I–II, 
by-case basis (Fassnacht et al. 2018).
2.3.7.2. Disseminated disease
The prognosis for recurrent or metastatic ACC is poor and no curative treatment is 
available. Therefore, treatment of disseminated ACC aims to alleviate symptoms and 
extend patient survival. Decisions should always be made individually, according 
to the expert clinical judgement from a multidisciplinary team.
The most common sites to which ACC spreads include the periadrenal tissue, 
lymph nodes, lungs, liver and bones (Abiven et al. 2006). Both locally recurrent ACC 
and singular metastases in the liver or lungs can be treated surgically. However, 
surgical resection is only recommended if a radical result can be achieved. Palliative 
If complete resection is impossible, other local treatment methods, such as radiation, 
radiofrequency ablation, cryoablation, microwave ablation or chemoembolisation 
can be used. 
For any form of disseminated disease, mitotane treatment is recommended. 
Furthermore, in aggressive cases of ACC, a chemotherapy combination consisting of 
2.3.7.3. Follow-up
After a complete ACC resection, regular follow-up should include clinical assessment, 
radiological imaging and biochemical evaluation for hormonal excess. The timeline 
following 3 years. After 5 years, the follow-up frequency can be adjusted. CT or MRI 
scans of the chest, abdomen and pelvis should detect regional recurrence or spread 
in the abdominal cavity, as well as metastasis to the liver and lungs. More extensive 
imaging may be performed for suspected metastasis in other locations. Signs and 
symptoms of tumour spread as well as tolerance for possible adjuvant therapy is 
assessed clinically during each visit. In the case of a hormonally active primary 
tumour, the particular hormone should be assessed biochemically (Fassnacht et 
al. 2018).
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2.4. Markers of malignancy
When considering the distinction between benign and malignant tumours, 
malignancy
and recurrence accompany ACCs. In the presence of any of these characteristics, a 
these characteristics, the nature of the tumour must be assessed using malignancy 
amongst malignant tumours, a  is necessary in order to 
been studied to reliably diagnose ACTs and to evaluate prognosis. The most relevant 
markers are categorised as histopathological markers, proteins and genetic markers 
Before proceeding, however, I address a quantitative marker of malignancy not 
A large tumour size associates with malignancy. Adenomas are primarily less 
than 5 cm in diameter. For a carcinoma, however, the median size exceeds 10 cm, 
and rarely measures less than 4 cm. Thus, size can be used to predict malignancy. In 
used to predict malignancy and favour surgical treatment. Furthermore, in the TNM 
staging, a tumour size of 5 cm distinguishes between T1 and T2. However, rare 
large adenomas and small carcinomas impair the diagnostic power of the tumour 
size as an independent parameter in predicting malignancy (Fassnacht et al. 2016). 
2.4.1. Histopathological markers
The same histopathological features associated with malignancy in any tumour 
type, including cytological atypia, growth pattern, mitotic activity, necrosis and 
invasion, also serve as markers of malignancy in ACTs. Diagnostic scoring systems 
and algorithms combining these features have been developed to diagnose ACTs 
accurately as well as to predict the prognosis of tumour patients.
The Weiss scoring system is the most widely used histological diagnostic 
system in use globally, and serves as the reference system for other diagnostic 
methods and scorings. The system was introduced by Dr. Weiss in 1984, a system 
associated with malignant behaviour and a worse prognosis. Table 6 summarises 
the criteria of the Weiss system. A tumour receives one point for each criterion it 
the total Weiss score inversely correlates with survival, whereby the higher the 
score, the worse the prognosis (Weiss 1984; Weiss et al. 1989).
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Table 6. The Weiss (1984) histological criteria. 
Nuclear atypia*
Mitoses >5/50 high-power field
Atypical mitoses






* According to the Fuhrman grade: grades 3−4 define nuclear atypia (Fuhrman et al. 1982).
The Weiss scoring system is quite sensitive in diagnosing a carcinoma. Furthermore, 
the Weiss score can be determined from basic hematoxylin and eosin (HE) stained 
slides, whereby no special stains or IHC is necessary. However, the Weiss system 
a low score on the malignant scale never recur or metastasise. In addition, the 
variation in their interpretation, thus limiting the reliability of diagnosis (Aubert 
et al. 2002; Tissier et al. 2012).
To render the diagnostic process more simple and objective, Aubert et al. (2002) 
These criteria were then weighted using a regression parameter to achieve the best 
correlation with the Weiss score. The calculation, 2x mitotic rate + 2x eosinophilic 
cytoplasm + atypical mitoses + necrosis + capsular invasion, yields the revised 
Weiss score, summing values from 0 to 7. Scores from 3 to 7 indicate a malignancy. 
Thus, despite representing a more objective system, the revised Weiss system only 
of the Weiss system remained unimproved.
Volante et al. (2009) introduced a diagnostic algorithm for ACTs, based on 
examining the reticulin structure of the tumour. In a carcinoma, the reticulin 
following criteria: mitosis frequency >5/50 HPF, the presence of necrosis or vascular 
invasion. The reticulin algorithm was compared to the Weiss score and appeared 
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reproducibility of the reticulin stain evaluation in an extensive study. 
Other diagnostic systems include scoring systems developed by Hough et al. 
(1979) and van Slooten et al. (1985). The Hough system combines histological with 
clinical criteria. The van Slooten system, in comparison, relies on purely histological 
criteria with weighted values. Neither of these systems has been widely used in 
clinical practice.
The diagnostic and prognostic assessment of oncocytic ACTs is more challenging 
than that of conventional tumours. The Weiss scoring system overestimates 
malignancy, since three of the Weiss criteria (eosinophilic cytoplasm, nuclear atypia 
outcome and prognosis than conventional carcinomas. To improve the diagnostic 
diagnostic system. The Lin–Weiss–Bisceglia system combines six Weiss criteria 
with the size of the tumour. This system includes three major criteria: a mitotic 
rate >5/50 HPF, atypical mitoses and venous invasion. In addition, the system has 
four minor criteria: necrosis, sinusoidal invasion, capsular invasion and a tumour 
size >10 cm and/or weight >200 g. The presence of one major criterion indicates 
malignancy, whereas the presence of one minor criterion indicates an uncertain 
malignant potential. The absence of all criteria indicates a benign tumour. WHO 
recommended this system in 2017.
Myxoid ACTs remain rare, and only single cases or small series have been 
reported. Myxoid change appears in varying degrees in these tumours (de Krijger 
et al. 2012). Papotti et al. (2010) suggested categorising myxoid tumours into two 
a nested, glandular or trabecular growth pattern and mild cytological atypia (type 
the same histological features as in the conventional component (type 2). Papotti et 
problem lies in the fact that type 1 tumours present with a much worse prognosis 
pattern. It appears that these type 1 tumours indeed form a particular tumour 
group and that these tumours can progress to a more malignant form. The Weiss 
scoring system is, thus, not appropriate for myxoid tumours. 
systems. A high mitotic count associates with both malignancy and a worse prognosis 
(Assie et al. 2007; Blanes et al. 2007; Miller et al. 2010; Stojadinovic et al. 2002; 
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with the same value used in the revised Weiss score (Aubert et al. 2002), in the 
Giordano et al. 2011). Adding the grade to the ENSAT staging system enhanced 
its accuracy to predict recurrence and survival amongst carcinoma patients (Miller 
been applied in clinical practice thus far, although the ESE practical guidelines for 
managing ACC recommend determining the exact mitotic count for every ACC 
(Fassnacht et al. 2018).
ACTs amongst children remain rare, and most often associate with hereditary 
tumour syndromes. The diagnostic and prognostic systems designed for adult 
patients do not adapt well to children, since they overestimate malignancies in 
children. In other words, with a histologically similar tumour, children have a better 
prognosis than adults (Michalkiewicz et al. 2004; Wieneke et al. 2003). A diagnostic 
system based on the tumour weight, invasion to adjacent tissues and the presence 
of metastasis has been proposed for children’s tumours (Dehner et al. 2009).
2.4.2. Immunohistochemical (IHC) markers
The proliferation activity is a strong predictor of malignancy as well as the clinical 
outcome in ACT patients (Beuschlein et al. 2015; Morimoto et al. 2008; Soon et 
al. 2009; Terzolo et al. 2001; Wachenfeld et al. 2001). Proliferation is assessed 
by immunohistochemical (IHC) staining of the cell cycle protein Ki-67. Although 
carcinomas present with a higher proliferation than adenomas, setting an applicable 
(Arola et al. 2000; Soon et al. 2009; Wachenfeld et al. 2001).
Proliferation has proved particularly useful for prognostic purposes. In 2018, 
recurrence consisted of the tumour stage, the resection status (R0/R1) and the 
proliferation. In its clinical practice guideline, ESE recommends categorising these 
patients into two groups. The low- to moderate-risk group includes patients with 
III, R1 or Ki-67 >10%. Adjuvant therapy is recommended for all high-risk patients. 
strategy (Fassnacht et al. 2018). However, Ki-67 is not a predictive factor when it 
33
In addition to the immunostaining of Ki-67, insulin-like growth factor 2 
(IGF-2) is the only IHC marker recommended by WHO to distinguish between 
adenomas and carcinomas (Lloyd et al. 2017a). Indeed, IGF-2 expression appears 
to associate with malignancy in a number of studies (Heaton et al. 2012; Soon et 
al. 2009, Wang et al. 2014). The physiological role of IGF-2 is related to growth 
IGF-2 gene is located at the imprinted 
locus 11p15. Structural and functional abnormalities at 11p15 are associated with 
ACC (Gicquel et al. 1997), as well as with IGF-2 immunostaining. That is to say, 
activation of this developmental gene following the embryological period results 
in oncogenesis. Interestingly, IGF-2 expression has proved particularly useful in 
predicting malignancy in tumours with a low proliferation (Soon et al. 2009). 
An increased ß-catenin IHC expression appears in all ACTs, although staining is 
more intense in carcinomas than in adenomas (Tissier et al. 2005). The localisation 
primarily expresses in the cytoplasm and cell membrane, whereas in carcinomas, 
nuclear staining is prominent (Gaujoux et al. 2011). Nuclear staining has been 
associated with an activating mutation to the ß-catenin gene and a worse prognosis 
in carcinomas (Kovach et al. 2015). Immunostaining of ß-catenin also indicates an 
activated Wnt/ß-catenin pathway, which I will return to below.
Aberrant protein 53 (p53)
a poor prognosis (Waldmann et al. 2012). Only a fraction of these tumours harbour 
a mutation of the tumour suppressor gene p53, although even some germline 
mutations are detected amongst sporadic ACCs. Aberrant p53 IHC associates with 
a higher proliferation in ACC.
The expression of cyclin E correlates with both malignancy and adverse 
prognosis in ACT (Tissier et al. 2004). Cyclin E is a progressor of the cell cycle and 
its overexpression has been described in various neoplasias. However, its particular 
role in ACC remains unclear. Tissier F et al. (2004) found no correlation between 
cyclin E expression and the overproduction of IGF-2. 
Steroidogenic factor 1
diagnosis of adrenal tumours to indicate an adrenocortical origin. SF1 is expressed 
in both the foetal and adult adrenal cortex. Recently, staining intensity was found to 
associate with a worse prognosis in ACC (Duregon et al. 2013; Sbiera et al. 2010).
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2.4.3. Molecular changes in adrenocortical neoplasia
The genetic background of adrenocortical neoplasias has been examined with 
increasing intensity in recent decades. The motivation for this research focuses 
on four primary goals: to understand the pathogenesis of these tumours, to more 
accurately diagnose these tumours, to classify tumours according to prognosis and, 
most recently, to identify targets for individualised therapies. 
With the advances in genetic methodology, an increasing amount of information 
has allowed for the integrated genomic characterisation of adrenocortical neoplasias. 
Regardless of the method, recurrent themes stand out: the expression of IGF-2, 
an alteration in p53 and the activation of the Wnt/ß-catenin pathway can discern 
tumours according to malignancy and prognosis. Figure 6 illustrates these primary 
IHC markers previously described (Assie et al. 2014). The molecular mechanisms of 
adrenocortical tumourigenesis relevant to this research are discussed further below.
Figure 8. Molecular classification of adrenocortical tumours according to genomic information (Assie et 
al. 2014). Published with permission from Macmillan Publishers Ltd.
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2.4.3.1. Wnt/ß-catenin pathway
The role of the Wnt/ß-catenin pathway in adrenocortical tumourigenesis is 
noteworthy since it is involved in both benign and malignant tumours. In 
addition, it is mutually exclusive with p53 alterations. The Wnt/ß-catenin pathway 
transmits signals from outside the cell through a chain of protein interactions to the 
nucleus, leading to the regulation of gene transcription related to cell proliferation, 
receptor leads to the accumulation of ß-catenin in the cytoplasm and its translocation 
to the nucleus, where it acts as a transcriptional coactivator. Without Wnt, ß-catenin 
degrades. Under physiological conditions, Wnt signaling is closely regulated. The 
activation of the pathway can, in principal, result from various alterations concerning 
the system, such as activating mutations or the upregulation of its components, 
inactivating mutations or downregulation of its inhibitors or alterations in the 
pathways interacting with the Wnt/ß-catenin pathway (Clevers et al. 2012). In ACTs, 
activating mutations of the ß-catenin gene CTNNB1 have been associated with 
tumourigenesis in both benign and malignant tumours. These are all mutations of 
exon 3, which protect ß-catenin from targeted degradation (Gaujoux et al. 2011; 
Tissier et al. 2005). The second established mechanism was discovered via studies 
of patients with familial adenomatous polyposis. These patients have an inherited 
heterozygous germline mutation of the APC gene. In addition to developing 
numerous intestinal polyps, they also show an increased incidence of desmoid 
tumours (De Marchis et al. 2017) and ACTs (Marchesa et al. 1997). This results 
from the APC protein being part of the ‘destruction complex’ of ß-catenin and, 
thus, inactivated APC fails to degrade ß-catenin. However, inactivating mutations 
in APC are primarily associated with ACAs and rarely with carcinomas, whilst APC 
mutations involve sporadic ACTs rather infrequently (Gaujoux et al. 2010). Increased 
IHC staining of ß-catenin appears in basically all ACTs, with cytoplasmic staining 
predominating in adenomas and nuclear staining in carcinomas. Yet, mutations 
of the ß-catenin gene and APC only account for a small proportion of these cases 
must be involved in the Wnt activation in ACTs.
2.4.3.2. C-myc: A multifunctional transcription factor and a proto-oncogene
C-myc is a transcription factor expressed universally in all cells, which induces the 
expression of various target genes involved in proliferation, cell growth, loss of 
is precisely regulated. C-myc is activated by mitogens, growth factors and via 
multiple signaling pathways. Both the overexpression of c-myc and the deregulation 
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of its expression or function can lead to a cell’s malignant transformation. The 
al. 1982) and has since been described in many cancers (Bai et al. 1994; Calcagno 
et al. 2009; Pietilainen et al. 1995). 
Unsurprisingly for a transcription factor, the c-myc protein is normally evident 
in the nuclei of tumours presenting with an over- or deregulated expression of the 
c-myc gene. Nonetheless, cytoplasmic c-myc is also evident in some neoplasias 
(Bai et al. 1994; Calcagno et al. 2009; Pietilainen et al. 1995; Ruzinova et al. 
2010), correlating with cancer aggressiveness. The role of cytoplasmic c-myc has 
been studied rigorously by Conacci-Sorrell et al. (2010; 2014), who presented a 
truncated, transcriptionally inactive cytoplasmic c-myc protein called myc-nick, 
which promotes cancer cell survival and augments cancer cell motility. They also 
showed that myc-nick expresses in a wide range of tumours. Myc-nick is generated 
in response to metabolic and cytotoxic stress by calpain-mediated proteolysis, under 
which conditions the full-length c-myc would cause cell death by apoptosis. 
Surprisingly, in ACCs, the underexpression of c-myc has been described as a 
pathogenic event (Szabo et al. 2010; 2011). A decreased c-myc expression has been 
suspected in the pathway analysis of gene expression microarray and comparative 
genome hybridisation studies, indicating that it is connected to deletions in 
have been found in adrenocortical neoplasias (Giordano et al. 2009; de Reynies 
et al. 2009). Interestingly, the Wnt/beta-catenin pathway, one of the signaling 
pathways leading to the induction of c-myc expression, has been connected to the 
c-myc and adrenocortical neoplasia (Berthon et al. 2010; Bonnet et al. 2011; Durand 
et al. 2011; Gaujoux et al. 2011; Parviainen et al. 2013; Ragazzon et al. 2010; Tissier 
et al. 2005). 
In adrenocortical neoplasia, Liu et al. (1996; 1997) studied c-myc gene expression. 
They found that c-myc mRNA expresses abundantly in normal adrenocortical tissue, 
hormonally inactive carcinomas and cortisol- or aldosterone-secreting adenomas. 
Hormonally active carcinomas and testosterone-producing adenomas presented 
with a decreased level of c-myc mRNA. Furthermore, they also found a solid 
correlation between the mRNA expression and nuclear IHC staining. Suzuki et al. 
(1992) studied the IHC expression of the c-myc protein in ACTs. They observed the 
expression of the c-myc protein in the nuclei of all 15 tumours studied. Furthermore, 
in carcinomas, c-myc staining also occurred in the cytoplasm.
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2.4.3.3. Isocitrate dehydrogenase (IDH): A metabolic enzyme and  
a proto-driver-oncogene
IDH is a metabolic enzyme. In its wild type, IDH is responsible for the oxidation 
+ to NAD(P)H. The 
mutated form of IDH prompts neomorphic activity, resulting in the conversion 
accumulation of the oncometabolite results in epigenetic dysregulation through 
IDH exists in three isoforms: 1, 2 and 3. Oncogenic mutations have been detected 
in isoforms IDH1 and 2, and following their recognition in gliomas, mutations have 
been reported in several neoplasias (Amary et al. 2011; Borger et al. 2012; Mardis 
et al. 2009; Murugan et al. 2010). All reported pathogenic mutations of IDH1 and 
2 are heterozygous missense point mutations that alter the conserved binding site 
of the homodimer enzyme. These most often occur at codon R132 in IDH1 and 
codons R140 or R172 in IDH2 by replacing arginine with another amino acid.
In gliomas, IDH mutation status represents an important diagnostic and 
in most lower-grade gliomas and secondary glioblastomas, indicative of a distinctive 
R132H mutation to IDH1 accompanies approximately 80% of all IDH mutations in 
gliomas (Hartmann et al. 2009). To improve the diagnostic procedure for gliomas, 
Capper et al. (2009) developed an antibody that binds to the mutated site of IDH1 
have not been reported in ACTs.
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3 AIMS OF THE STUDY
The primary aim of this study was to identify diagnostic preoperative and 
postoperative markers of malignancy in ACTs to achieve tailored management of 
patients with adrenal lesions.
The detailed aims were as follows:
1. To identify an optimal unenhanced CT attenuation value to depict tumours 
requiring further examination. To achieve this aim, the correlation between 
the proportion of lipid-poor eosinophilic cells in ACTs was examined.
2. To optimise a scoring system for ACTs to predict their metastatic potential. To 
achieve this aim, the diagnostic power of the Weiss scoring system in relation 
to our cohort needed to be determined.
to elucidate their role in adrenocortical carcinogenesis and, thus, testing their 
potential use as biomarkers for malignancy. 
4. To study the prognostic and predictive role of IDH1 R132H IHC staining in 
ACTs, as well as to identify the genetic alterations behind the positive staining 
result. 
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4 MATERIALS AND METHODS
4.1. Patient cohorts and clinical data
Figure 9 and Table 7 summarise the patient and tumour cohorts. Across all studies, 
our cohorts included adult patients who underwent surgery for a primary ACT 
in the Department of Surgery at Helsinki University Central Hospital (HUCH). 
Tumour specimens were stored in the archives of the Department of Pathology at the 
were collected from patient records. The functional status of the tumours was based 
on the presence of a clinical and/or biochemical adrenocortical hypersecretion. 
Survival and cause of death data were collected from the Population Register Centre 
and Statistics Finland.
Figure 9. Tumour cohorts in studies I−IV. Study I: 79 tumours operated on between 2002 and 2008. 
Study II: 177 tumours operated on between 1990 and 2003. Studies III and IV: 197 tumours operated on 
between 1990 and 2003.
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Table 7. Clinical and histological characteristics of the study cohorts in the original publications.
Study I II III–IV
Patients 78* 175** 195**
Tumours
all 79 177 197
local 76 163 183
metastatic 3 14 14
Age (years)
range 18–83 24–82 24–82
mean 56 53 54
median 57 54 55
Gender
male 24 58** 66**
female 54* 117** 129**
Side
right 35 93 101
left 44 84 96
Size (cm)
range 0.8–19.3 0.5–28.0 0.5–28.0
mean 3.4 3.4 3.4
median 2.6 2.0 2.0
Weiss score
0–2 68 147 166
3–9 11 30 31
Hormonal secretion
Aldosterone n 34 92 96
% 43 52 49
Cortisol n 26 68 74
% 33 38.4 38
Androgens n 2 11 11
% 3 6 6
Inactive n 18 20 29
% 23 11 15
*One female had two separate local tumours.
**One male and one female had two separate local tumours.
In study I,
pathology database. The study cohort included tumour patients who had appropriate 
preoperative unenhanced CT scans available for retrospective re-evaluation. 
Amongst 171 excised tumours, 79 tumours (78 patients, including one patient with 
two separate benign tumours) were included in this study. In this study, tumour size 
was based on information in the Department of Radiology database. To compare 
lipid-rich adenomas, lipid-poor eosinophilic adenomas and malignant tumours, 
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the tumours were divided into three groups according to the lipid content and the 
level of malignancy. Group 1 included lipid-rich adenomas, group 2 consisted of 
lipid-poor eosinophilic adenomas and group 3 consisted of histologically malignant 
a lipid-poor eosinophilic adenoma. Two pathologists evaluated the percentage of 
lipid-poor eosinophilic cells in each tumour.
In studies II through IV (IHC), patients who underwent surgery between 
whereby two patients had two separate tumours. Studies III and IV included all 
197 tumours.
Study IV (genetics) used tumour material in the genetic analyses, as illustrated 
by Figure 10. For amplicon-based hotspot panel sequencing of the IDH1 gene, we 
selected 10 tumours with a Weiss score of 3 to 9: 5 tumours which exhibited a 
strong positive and 5 featuring a negative IDH1 R132H IHC staining. For IDH1 exon 
sequencing from the FFPE tumour material, we chose an additional 10 tumours: 
5 tumours with a Weiss score of 0 to 2 with a positive IDH1 R132H IHC stain and 
5 tumours with a Weiss score of 3 to 9 with a low positivity. Thus, 20 tumours in 


















Figure 10. Tumour material in study IV, according to the histological malignancy and IDH1 R132H 
immunohistochemical (IHC) staining. Amongst the 195 tumours for which IDH1 R132H IHC was available, 
162 tumours were adenomas (Weiss score 0−2) and 33 tumours were carcinomas (Weiss score 3−9). The 
horizontal line indicates the IDH1 R132H IHC staining of the tumours: positive vs. negative. Smaller circles 
show the cases selected for amplicon-based hotspot panel sequencing (NGS) and the fresh-frozen samples 
used for the exon sequencing.
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4.2. Radiological imaging
the HUCH district and all data were obtained from the shared radiology database 
all these hospitals use. The slice thickness ranged from 2.5 mm to 7 mm. In 31 
cases, thin slices (3 mm or less) were available; in 48 cases, the thickness was over 
3 mm. An experienced adrenal radiologist re-evaluated the CT scans. The maximal 
tumour diameter was determined using a distance cursor in the axial plane. The 
attenuation (HU) values were recalculated using a circular region-of-interest cursor 
placed over the area of the tumour, avoiding the edges as well as the necrotic and 
cystic areas to prevent partial volume artefacts. One to three measurements were 
obtained for each tumour. The mean HU value was recorded.
4.3. Histopathological re-evaluation
embedded tissue samples. The histopathological diagnosis according to the Weiss 
criteria (Weiss 1984; Weiss et al. 1989) was determined for each tumour, which 
received a numeric score ranging from 0 to 9. Table 6 summarises the Weiss criteria.
4.4. Tissue microarray (TMA) blocks
Tissue microarray (TMA) blocks were constructed from archived surgical formalin-
tumours, six cores were obtained using a semiautomatic TMA instrument (Beecher 
Instruments, Silver Spring, MD, USA) with two cores also taken from the normal 
adrenal cortex.
4.5. Molecular analysis of tumours
4.5.1. Immunohistochemistry and scoring
Immunohistochemistry (IHC). Sections from TMA blocks 4-μm-thick were 
8 summarises the antibody clones, dilutions, manufacturers, pretreatment and 
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endogenous peroxidase-blocking procedures. Slides were counterstained with 
Two pathologists independently completed the scoring in studies III and IV. 
Any discrepancies between the evaluations were discussed until consensus was 
reached. Scorings of Ki-67 and cyclin D1 were conducted using the ImmunoRatio 
image analysis software, described below. The details of scorings used appear in 
Table 8.
4.5.2. Amplicon-based hot spot panel sequencing
Maxwell® LEV Blood DNA Kit (Promega Corporation, Madison WI, USA) according 
to the manufacturer’s instructions. The tumour content of each sample was evaluated 
from HE-stained slides by an experienced pathologist. 
DNA was subjected to library preparation with the Ion AmpliSeq Cancer Hotspot 
Panel version 2, designed to target 2800 COSMIC mutations from 50 oncogenes and 
tumour suppressor genes, and then sequenced on the Ion Torrent PGMTM System 
IDH1 
including the R132 and IDH2 genes, respectively. Library preparation, template 
preparation and the sequencing were completed according to the manufacturer’s 
instructions (Life Technologies, Carlsbad, CA, USA). Data analysis was carried 
out with the Torrent Suite Software version 4.0. After trimming and alignment 
to the hg19 human reference genome, sequence variants were detected using the 
out noncoding and polymorphic variants.
4.5.3. Hybridisation capture-based targeted sequencing
To prepare the paired-end libraries, 7000 to 32 000 ng of DNA extracted from FFPE 
of DNA was used as the input (ThruPlex DNA-Seq Kit, Rubicon Genomics). Target 
enrichment was performed using the SeqCap EZ Comprehensive Cancer panel 
(Roche Nimblegen). This panel covers 9 exons and the 5’ untranslated region (UTR) 
of the IDH1 gene, including the mutation sites of the Hot Spot Panel version 2. The 
enriched libraries were sequenced using the HiSeq2000 instrument with a paired-
end 100-bp read length. Sequence analysis and variant calling were performed by 
an in-house bioinformatics pipeline (VCP, Variant Calling PipelineVCP (Sulonen 
et al. 2011)). In addition to the variant-calling algorithms, IDH1 mutation hotspot 
Viewer (IGV (Robinson et al. 2011)). Library preparation, sequencing, variant calling 
and data analysis on this experiment were performed by the FIMM Sequencing 
Unit, HiLIFE, University of Helsinki, Finland.
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Assessing the percentage of positive tumour cell nuclei in Ki-67 and cyclin D1 
stainings was conducted using an internet-based open-source image analysis 
software called ImmunoRatio, which can be used in the quantitative assessment 
of any nuclei markers (Tuominen et al. 2010). Image capture was performed using 
a Nikon Eclipse 80i light microscope (40x objective) connected to a Digital Sight 
DS-5M (Nikon) digital camera and NIS-Elements F 3.0 image capture software. 
From each core biopsy, one digital image (JPEG format, Resolution 1280 x 960) 
was captured from the area of highest positivity, covering 50% of the core biopsy. 
With ImmunoRatio’s Advanced Mode setting, threshold values for hematoxylin (0) 
and 3,3’-diaminobenzidine (DAB) (-10) were adjusted, with no correction equation. 
images. Image analysis settings remained identical after light exposure (manual 
exposure, 10 ms, gain 1x), and the thresholds were considered good. Figure 11 
shows two examples of the original image and the pseudoimage created using 
ImmunoRatio, from which the percentage of positive nuclei was calculated. From 
all images available for each tumour, the highest count was recorded.
Figure 11. Two examples of defining proliferation index using ImmunoRatio. ImmunoRatio uses the original 
immunostaining (the upper image) to create a pseudoimage (the lower image), from which the precise 
proliferation index is calculated.
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4.7. Statistical analysis
In study I
in the unenhanced CT attenuation value (HU) between the three tumour groups 
(lipid-rich adenomas, lipid-poor adenomas and malignant tumours) was assessed 
comparisons in pairwise comparisons. The correlation of the total Weiss score as 
well as the eosinophilic cell count with the unenhanced CT attenuation value (HU) 
was assessed with the Spearman’s rank correlation test. We considered p < 0.05 as 
20.0 software (IBM SPSS Statistics, SPSS Inc., Chicago, IL, USA).
In studies II through IV, results are reported as the mean, median and range, 
 
and the metastatic status. 
method and the log-rank test compared survival curves. We considered p < 0.05 
performed using SPSS version 20 (IBM, New York, NY, USA) or with Statexact 
version 4 (Cytel Inc., Cambridge, MA, USA) in study II, with SPSS version 22 
(IBM, New York, NY) in study III and using SPSS version 24 (IBM, New York, 
NY, USA) in study IV.
scores were tested using the nonparametric paired McNemar’s test. Logistic 
regression and receiver-operating characteristic (ROC) analyses served to model 
the new score developed here. Logistic regression with backward stepping was 
4.8. Ethical approvals
This study was approved by the local ethics committee (Dnro HUS 226/E6/06, 
extension TMK02 §66 17.4.2013) and the National Supervisory Authority of Health 
and Welfare (TEO Dnro 10041/06.01.03.01/2012).
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5 RESULTS
5.1. Unenhanced CT attenuation value to assess adrenal tumours 
(study I)
The total Weiss score correlated with the unenhanced CT attenuation value (HU) 
(rs p < 0.001). The higher the score, the higher the CT attenuation value. 
The eosinophilic cell count was unevenly distributed across the tumour 
material: most tumours contained either less than 30% or more than 80% 
eosinophilic cells. The unenhanced CT attenuation value correlated with eosinophilia 
(rs p < 0.001). However, some tumours showed a substantial deviation 
from the regression line. 
To compare the lipid-rich adenomas, lipid-poor eosinophilic adenomas and 
malignant tumours, we grouped tumours into three groups according to the lipid 
content and the level of malignancy. Here, we used one of the Weiss criteria (<25% 
eosinophilic cells and unenhanced CT attenuation value according to the tumour 
p < 
0.001). In the pairwise comparisons adjusted for multiple comparisons, lipid-rich 
than lipid-poor tumours (group 2) (p < 0.001) or malignant tumours (group 3) 
(p
malignant tumours (p
None of the malignant tumours had a CT attenuation value under 22 HUs.
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Table 9. Percentage of eosinophilic cells and unenhanced CT attenuation value (Hounsfield units, 
HU) according to tumour groups. Comparisons are based on Kruskal−Wallis ANOVA. Groups 1 








tumours 54 14 11
Eosinophilia %
range 0−50 70−100 80−100
median 12.4 82.9 90
Hounsfield units
range -10−40 21−43 22−44
median 7 30 33
mean rank 28.7 63.2 65.8
Comparison 
between groups
1 vs 2          p < 0.001
1 vs 3                      p < 0.001
2 vs 3           p = 1.000
5.2. Optimising histological scoring systems:  
the Helsinki Score (study II)
either local or metastatic. Table 10 shows the distribution of the Weiss score in 
this material. The Weiss score was sensitive in distinguishing all metastatic 
carcinomas. However, a number of local tumours were falsely diagnosed as 
malignant. In diagnosing a metastatic ACC, the sensitivity of the Weiss system 
see Table 12).
The proliferation index (PI) of the tumours was assessed using the Ki-67 
stainings relying on the ImmunoRatio image analysis software. Table 10 shows 
the range, mean, median and interquartile range (IQR) of the PI in this material. 
p < 0.01) was 
Logistic regression with backward stepping was used to identify the most 
This led us to a scoring model, called the Helsinki score: 3.28 x mitotic rate + 4.42 
+ proliferation index (see Figure 12). ROC analysis was used to determine the 
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Figure 12. The Helsinki score = (3 x mitotic rate > 5/50 HPF + 5 x necrosis + proliferation %), illustrated by 
examples of each of these three parameters.
Table 10. Distribution of tumours according to the Weiss score, the Helsinki score and the 
proliferation in local versus metastatic tumours.
All Local Metastatic
Number of tumours 177 163 14
Weiss score
0−2 147 147 0
3−9 30 16 14
Helsinki score
<8.5 162 162 0
8.5 15 1 14
Proliferation %
range 0−54.2 0−8.0 0.9−57.2
mean 2.3 1.0 16.7
median 0.8 0.7 7.0
IQR 1.0 22.5
IQR, interquartile range
 diagnosed a metastatic ACC with 
The comparison of the Helsinki score to the Weiss score in this series appears in 
Tables 11 and 12. Only one tumour earned a false-positive result using the new 
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according to both scoring systems, with a Weiss score of 9 and a Helsinki score of 
11.3. The tumour was large (28 cm) and locally invasive, but radically excised. This 
patient received mitotane treatment following surgery, and was alive at the end of 
the follow-up period 8 years after surgery. 
 




<8.5 147 15 162




Table 12. Sensitivity and specificity in diagnosing metastatic adrenocortical carcinoma (ACC) 





















A Helsinki score higher than 8.5 correlated with survival (see Figure 
13). Based on their Helsinki score, tumours were categorised into three groups: 
1) benign tumours with a Helsinki score of 0 to 8.5; 2) malignant tumuors with 
a Helsinki score of 8.5 to 17; and 3) malignant tumours with a Helsinki score of 
vs. group 2, p < 0.01; group 1 vs. group 3, p < 0.01; group 2 vs. group 3, p
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Figure 13. Survival according to the Helsinki score.
5.3. Molecular markers of malignancy
5.3.1. Transition of c-myc expression from the nucleus to cytoplasm indicative of 
malignant transformation (study III)
ACTs show both nuclear and cytoplasmic staining of c-myc. Table 13 shows 
how the staining  tumours. In benign 
cortex (data not shown). In metastatic carcinomas, the cytoplasmic staining was 
typically strong and nuclear staining appeared weaker than in adenomas. Figure 
14 shows the typical staining patterns of c-myc in adenomas and carcinomas. The 
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Table 13. Distribution of immunohistochemical (IHC) scores in studies III and IV. The Fisher’s 
exact test compared IHC scores between local and metastatic tumours.
All Local Metastatic p value




range 0−3 0−3 1−3
<0.001mean 1.4 1.3 2.6
median 1.0 1.0 3.0
nuclear
score 0−4
range 0−4 0−4 0−4
0.011mean 3.1 3.2 2.1
median 4.0 4.0 1.5
cytoplasmic-to- 
nuclear ratio
0.75 142 141 1
<0.001
>0.75 50 37 13
p27 %
range 0−100 0−100 20−100
0.307mean 53.8 53.0 63.6
median 70.0 70.0 75.0
Cyclin E %
range 0−80 0−80 0−60
0.001mean 8.7 7.7 21.4
median 5.0 5.0 15.0
Cyclin D1 %
range 0−90 0−90 0−50
0.227mean 12.6 12.1 18.6
median 5.0 9.0 16.5
IDH1 R132H
score 0-3
range 0−3 0−3 0−2
0.699mean 0.4 0.4 0.3
median 0 0 0
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Figure 14. Typical staining pattern of c-myc in an adenoma and a carcinoma. A) An adenoma shows strong 
nuclear c-myc staining and no cytoplasmic staining. B) A carcinoma shows strong cytoplasmic c-myc 
staining and weak to no nuclear staining. Images: 400x objective.
local tumours from metastatic tumours was 3 (p < 0.001 and p 
investigate the importance of the localisation of the c-myc protein, we calculated the 
ratio of cytoplasmic to nuclear c-myc for each tumour. In order to avoid dividing 
p < 0.001). 
local tumours from metastatic tumours was 0.75 (p < 0.001). 
Cytoplasmic c-myc staining correlated with the total Weiss score 
for the tumour (Rs p < 0.001) and with the Helsinki score (Rs  p 
< 0.001). The cytoplasmic-to-nuclear c-myc ratio also correlated with the Weiss 
score (Rs p < 0.001) and the Helsinki score (Rs p
nuclear c-myc staining did not correlate with the Weiss (p
score (p
Kaplan–Meier survival
cytoplasmic and nuclear staining and survival (log-rank test, p < 0.001 and p
0.008). 
 cyclin D1, p27 and cyclin E were also studied to 
investigate the correlation of c-myc expression to molecules associated with the 
signaling pathway. The distributions of nuclear cyclin D1, p27 and cyclin E IHC 
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cyclin D1 or p27 between local and metastatic tumours was found (p
p
p
cyclin E expressions to each other appear in Table 14.
 
Table14. Correlations between the c-myc, cyclin D1, p27 and cyclin E expressions in adrenocortical 
tumours (ACTs). The Spearman’s rho correlation coefficient was calculated between different 




Cyclin D1 Rs = 0.148 
p = 0.040
Rs = 0.260 
p < 0.001
p27 Rs = 0.106
p = 0.144
Rs = 0.303 
p < 0.001
Rs = 0.388 
p < 0.001




Rs = 0.197 
p = 0.006
Rs = 0.143 
p = 0.046
5.3.2. Positive mutation-specific IDH1 R132H immunostaining indicates better 
prognosis amongst carcinoma patients (study IV)
The IDH1 R132H IHC staining appeared as a granular cytoplasmic positivity in 
ACTs. Similar staining appeared in the normal adrenal cortex. The intensity of the 
staining varied and was scored on a scale from 0 to 3.
The IDH1 R132H staining appeared in both benign and malignant tumours, 
and negative vs. positive staining did not distinguish between local and 
metastatic disease (p
R132H staining in this material.
The aldosterone secretion of the tumour correlated with a weak IDH1 R132H 
staining (R2 p
IDH1 R132H staining (R2 p
the IDH1 R132H staining and the testosterone secretion (R2 p
hormonal inactivity (R2 p
To examine the possible  of the IDH1 R132H staining 
R132H staining survived longer than patients with negative staining (p
To identify known mutations of IDH1 at Arg132, 10 tumours with Weiss 
scores of 3 to 9 were selected, 5 of which exhibited a strong positive and 5 of which 




For the IDH1 gene sequencing
tumour material, 10 additional tumours were selected: 5 tumours with Weiss scores 
of 0 to 2 with positive IDH1 R132H IHC staining and 5 tumours with Weiss scores 
of 3 to 9 with low positivity. In total, 20 tumours were analysed. Using hybridisation 
capture–based targeted sequencing, no informative sequencing data were received. 
Initial sequencing provided the mean target coverage of the sequencing depth after 
removing duplicates. Sequencing delivered depths of 115 to 505x; yet, after PCR 
duplicate removal, the informative depth diminished to 2x to 13x. Evidently, the 
linked and/or fragmented, thereby preventing successful library preparation. Such 
DNA behaves seemingly well in PCR amplicon-based methods, but lacks a true 
somatic resolution given the limited number of accessible DNA template molecules.
frozen tumour material was available from 16 tumours. Using the same protocol 
for the hybridisation capture–based targeted sequencing, depths ranging from 100 
to 500x after PCR duplicate removal were achieved, enabling the performance of 
somatic mutation calling. However, no known hotspot mutation nor any novel 
variants in the IDH1 gene nor the UTRs were found.
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6 DISCUSSION
6.1. Rising incidence due to incidentalomas
Characterising adrenal tumours has become an important clinical issue given 
the widespread use of radiological imaging and, thus, the increased incidence of 
clinically inapparent lesions, or ‘incidentalomas’. In addition, adrenal tumours 
are detected more often in ageing Western populations, since their incidence 
increases with age. Most adrenal tumours are benign cortical adenomas detected 
either through symptoms caused by excess hormone secretion or as incidental 
with a stable incidence of 1 to 2 cases per million population per year (Lloyd et al. 
2017a). Whilst carcinomas are primarily detected through symptoms related to 
In the preoperative assessment of adrenal tumours, phaeochromocytoma and 
metastasis to the adrenal gland must also be considered. Thus, patient history, 
clinical examination, biochemical measurements and radiological imaging all 
contribute to the initial evaluation (Fassnacht et al. 2016).
6.2. Unenhanced CT: the benign and the indeterminate
The primary modality for the radiological assessment of adrenal tumours is 
unenhanced CT. Characteristics such as a large size, uneven border, heterogenous 
malignancy. Lipids are radiotranslucent and, since most benign cortical adenomas 
are lipid-rich, a low attenuation value indicates a benign adenoma. In general 
guidelines, including the ‘Clinical Practice Guidelines for the Management of Adrenal 
Incidentalomas’ by the European Society of Endocrinology, the threshold is set at 
no further investigations are necessary. A tumour with any malignant features and/
or attenuation >10 HUs is considered indeterminate and must be further examined. 
Indeterminate tumours include both malignant tumours and benign adenomas 
containing fewer lipids, also referred to in radiological terms as lipid-poor adenomas. 
However, only one group has an established correlation between the lipid content 
and the unenhanced CT attenuation value in adrenocortical tumours (ACTs) 
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(Korobkin et al. 1996). Their material was small, consisting of 20 adenomas and 
ACTs that the proportion of eosinophilic lipid-poor cells correlates with the CT 
attenuation value or HUs. However, a large proportion of tumours >10 HUs were 
actually lipid-rich, whereby other factors contributed to the CT attenuation than lipid 
content alone. Furthermore, and more importantly from the patient’s point of view, 
all carcinomas had attenuation values >21 HUs. Thus, according to our material, 
the threshold for an indeterminate tumour could be raised from 10 to 20 HUs. 
Thus far, the CT attenuation threshold for indeterminate tumours has remained 
>10 HUs, achieving a maximum sensitivity in discerning a malignancy. In a meta-
analysis by ESE consisting of 18 adrenal tumour imaging studies, the imaging 
modalities and the background of the patients varied (Fassnacht et al. 2016). 
All unenhanced CT studies used the same attenuation threshold of >10 HUs for 
indeterminate tumours. The sensitivity in diagnosing a malignant tumour amongst 
pure incidentalomas was determined in only two studies, reaching 100% and 
95%. Sensitivity dropped to 93% amongst patients with a history of extra-adrenal 
dividing tumours accurately into benign and indeterminate is especially important 
to rule out as many patients as possible from further imaging examinations or 
follow-up. These examinations expose the patient to irradiation and cause mental 
As the incidence of incidentalomas increases, we should consider raising the CT 
attenuation threshold for indeterminate tumours, at least amongst patients with 
no history of malignancy. Furthermore, multicentre studies involving extensive 
material comparing the CT attenuation value of adrenal tumours with an accurately 
healthcare system as a whole. 
6.3. Characterising a malignancy: striving for accuracy
primary cause of a fatal outcome; thus far, metastatic disease cannot be cured. In 
nonmetastatic tumours, the malignant potential must be assessed histologically. 
Since many histological parameters associate with a malignancy, various histological 
scoring systems combining various parameters have been proposed as predicting 
malignancy as accurately as possible. The most widely used system is the Weiss 
system (Weiss 1984), which has served as the gold standard globally for several 
decades. Thus, most pathologists are familiar with the nine histological criteria in 
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the Weiss system. This system is sensitive in diagnosing ACCs, and the score also 
correlates with prognosis. However, pathologists are also painstakingly aware of 
in interobserver variation (Aubert et al. 2002; Tissier et al. 2012). Some tumours 
with borderline scores never recur or metastasise, thereby leading to questions 
apply to histological subtypes or children’s tumours (de Krijger et al. 2012; Dehner 
et al. 2009).
Proliferation using Ki-67 IHC staining has been used as an additional tool to 
assess malignancy and prognosis in ACTs (Beuschlein et al. 2015; Morimoto et al. 
2008; Soon et al. 2009; Terzolo et al. 2001; Wachenfeld et al. 2001). Where the 
diagnosing a malignancy. Some ACCs present with a low proliferation and are not 
Thus, we proposed a new scoring system to predict the metastatic potential of 
adult ACTs. The Helsinki score combines two of the most objective histological 
Weiss criteria with the proliferation index, achieving a reliable and powerful 
diagnostic system. The Helsinki score, calculated as 3 x mitotic activity >5/50 
on 225 ACCs, where the Helsinki score outperformed the Weiss score, mitotic index, 
proliferation and tumour stage as prognostic parameters. The extensive material 
also included oncocytic and myxoid tumours, verifying the prognostic value of the 
Helsinki score in these histological subtypes. Another study of 43 oncocytic tumours 
and reticulin algorithm in diagnosing a malignancy (Renaudin et al. 2018). The 
Helsinki score was by far the most powerful diagnostic system for oncocytic tumours. 
6.4. C-myc: the transition from nucleus to cytoplasm associates 
with malignancy
The overexpression of the transcription factor c-myc has been associated with 
multiple cancers (Bai et al. 1994; Calcagno et al. 2009; Pietilainen et al. 1995), 
Yet, the connection between c-myc expression and adrenocortical neoplasia has 
received very little attention. Only one study has described the IHC expression of 
c-myc in ACTs. In that study, c-myc expressed in the nuclei of all 15 tumours. In 
carcinomas, c-myc staining also occurred in the cytoplasm. (Suzuki et al. 1992). 
Furthermore, even the underexpression of c-myc in adrenocortical neoplasia has 
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been suggested based on the pathway analysis of the gene expression microarray- 
and comparative genome hybridisation studies (Szabo et al. 2010; 2011). However, 
one pathway leading to the c-myc expression, the Wnt/ß-catenin pathway, has been 
associated with adrenocortical neoplasia in various studies (Berthon et al. 2010; 
Bonnet et al. 2011; Durand et al. 2011; Gaujoux et al. 2011; Parviainen et al. 2013; 
Ragazzon et al. 2010; Tissier et al. 2005). 
We showed that ACTs express c-myc. C-myc appears in the nuclei of benign 
adenomas as well as in the normal adrenal cortex. In carcinomas, c-myc appears in 
the cytoplasm and clears from the nucleus. Cytoplasmic c-myc has also been found 
in other neoplasias (Bai et al. 1994; Calcagno et al. 2009; Pietilainen et al. 1995; 
Sorrell et al. (2010, 2014) rigorously studied the role of cytoplasmic c-myc. They 
presented a truncated, transcriptionally inactive cytoplasmic c-myc protein called 
myc-nick, which promotes cancer cell survival and augments cancer cell motility. 
Myc-nick is generated in response to metabolic and cytotoxic stress by calpain-
mediated proteolysis under which conditions the full-length c-myc would cause 
that myc-nick expresses in a wide range of tumours, hypothesising that it could 
represent the cytoplasmic c-myc immunostaining seen in some previous studies. 
The cytoplasmic c-myc in ACTs, however, does not appear to be myc-nick. The 
9E10 antibody we used for IHC binds to the C-terminus of the c-myc protein, which 
truncates in the myc-nick protein. It is possible that the cytoplasmic c-myc seen in 
ACTs represents a full-length c-myc protein retained in the cytoplasm under stress 
conditions, awaiting processing to myc-nick similarly to processes at the invasive 
cyclin E, cyclin D1 and p27 to further examine the role of c-myc. Our nuclear staining 
of cyclin E was higher in metastatic than in local tumours, agreeing with a previous 
study (Tissier et al. 2004). However, neither cytoplasmic nor nuclear c-myc staining 
correlated with cyclin E. Thus, c-myc and cyclin E appear to play independent 
roles in ACT development, suggesting that cyclin E may not be the target gene of 
c-myc in ACCs. Cyclin D1 showed a higher staining in metastatic tumours than in 
cytoplasmic c-myc expression and to a lesser extent with nuclear c-myc, suggesting 
a common inducer for the expression of both proteins. The inducer could be the 
Wnt/ß-catenin pathway targeting both cyclin D1 and c-myc in colon carcinomas 
(He et al. 1998) and also associating with adrenocortical neoplasia.
The expression of the cell-cycle inhibitor protein 27 (p27 or cyclin-dependent 
kinase inhibitor 1B) associates with a good prognosis in several cancers (Migita et al. 
2002; Nozoe et al. 2006). However, p27 plays a dual role in cancer, since elevated 
levels have been associated with a metastatic potential (Kouvaraki et al. 2002). 
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C-myc appears to inhibit the p27 expression. Our mean nuclear p27 staining was 
correlated with cyclin E. C-myc does not appear to inhibit p27 expression in ACTs, 
although the correlation with cyclin E indicates a possible role in inhibiting the cell 
Over all, the strong cytoplasmic c-myc and weak nuclear c-myc expression in 
ACTs associated with the metastatic potential and shorter survival. We hypothesise 
that the transition of c-myc from the nucleus to cytoplasm prevents c-myc from 
acting as a transcription factor and from inducing apoptosis. Further studies are 
necessary in order to uncover the mechanism of the c-myc function in ACTs.
6.5. Isocitrate dehydrogenase (IDH)
Oncogenic mutations of the metabolic enzyme IDH have been reported in several 
neoplasias (Amary et al. 2011; Borger et al. 2012; Mardis et al. 2009; Murugan et 
detected in gliomas, where these mutations indicate a distinctive pathogenesis and 
approximately 80% of all IDH mutations in gliomas (Hartmann et al. 2009). To 
improve the diagnosis of gliomas, Capper et al. (2009) developed an antibody that 
through IHC. 
in the normal adrenal cortex (oral communication), thereby increasing interest 
in the examination of  IDH1 R132H expression in ACTs. We found granular 
cytoplasmic immunostaining for IDH1 R132H in the normal adrenal cortex and 
in ACTs to varying degrees. IDH1 R132H IHC did not distinguish between local 
and metastasised disease. However, a positive IDH1 R132H IHC correlated with a 
or novel IDH1 mutations in ACTs. The epitope binding IDH1 R132H antibody in 
immunopositive and immunonegative carcinomas indicates that the epitope carries 
antibody to ACTs indicates that new experimental therapies such as small molecule 
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inhibitors of mutated IDH or peptide vaccines (Friedrich et al. 2018; Golub et al. 
6.6. Strengths and limitations 
A major advantage of this study is its large cohort size and the comprehensive clinical 
and follow-up data on all patients. That is, no patients were lost to follow-up. One 
limitation is the small number of rare metastatic carcinomas in a small population. 
In study I, the unenhanced CT attenuation value of tumours was compared 
to their histological diagnosis using the Weiss score. This represents a limitation 
since the Weiss score does not always reveal the true nature of a tumour. Some 
carcinomas in this material did not recur or metastasise. This limitation is shared 
with other studies, since it occurred in many studies where new diagnostic systems 
were developed. The diagnostic power has often been compared to that of the 
Weiss score, so that the diagnostic power has not improved. It would be better to 
metastasis or disease-related death. The Helsinki score was developed by identifying 
the prognostically most relevant factors achieving diagnostic accuracy. The CT 
diagnosis. 
One strength in study II, in establishing the Helsinki score, lies in that the 
(Mengel et al. 2002; Papathomas et al. 2016), whilst the proliferation index using 
variation remains a risk in assessing proliferation. The use of the proliferation index 
the fact that it has enjoyed success in grading neuroendocrine tumours (Klimstra 
et al. 2019).
6.7. Future prospects
in determining the proper treatment strategy for a tumour patient. With a rare 
disease like ACC, patients should be referred to a specialised unit where all members 
individualised care for a patient. New diagnostic methods using sophisticated 
technology such as liquid biopsy are currently being studied. In addition, new 
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with a tumour (Crona et al. 2018). Thus, Helsinki score version 2.0 should be 
developed. This could integrate aspects included in version 1.0 as well as molecular 
and possibly imaging data. 
The diagnosis of ACTs is based on histopathology, even with recent advances in 
molecular pathology. All further investigations of the tumour sample are decided 
experienced endocrine pathologist. In future, this could be achieved through digital 
consultation, where slides are scanned and can be assessed anywhere in the world. 
More broadly, the medical team including radiologists, endocrinologists, surgeons, 
oncologists and medical geneticists must keep abreast with new developments to 
ensure high-quality diagnostics and management of ACC. 
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7 CONCLUSIONS
The main conclusions from the studies presented here are as follows:
1. The proportion of eosinophilic lipid-poor cells in ACTs correlates with the 
CT attenuation value by HUs, although CT attenuation cannot distinguish 
between lipid-poor adenomas and carcinomas. All carcinomas exhibited 
attenuation values >21 HUs. Thus, according to this material, the threshold 
for an indeterminate tumour could be increased from 10 to 20 HUs, at least 
amongst patients with no history of malignancy.
2. The Helsinki score, relying on the mitotic frequency, the proliferation index as 
well as the presence of necrosis, accurately predicts the metastatic potential of 
ACTs, outperforming the diagnostic power of the Weiss scoring system. 
3. A strong cytoplasmic and weak nuclear c-myc expression in ACTs associate with 
malignancy and a shorter survival, suggesting that the transition of c-myc from 
the nucleus to cytoplasm may represent a pathogenic step in adrenocortical 
carcinogenesis.
4. Amongst ACCs, IDH1 R132H immunopositivity correlates with a better 
prognosis, although immunopositivity does not appear to associate with 
mutations to the IDH1 gene.
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